Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1487–1492. doi: 10.1158/1078-0432.CCR-21-3247

Figure 1: Trial Schema of SOPHIA.

Figure 1:

Abbreviations: HER2: human epidermal growth factor receptor 2; IRR: infusion-related reaction; MBC: metastatic breast cancer; PFS: progression-free survival; PI: principal investigator; T-DM1: ado-trastuzumab emtansine.

Source: Margetuximab Assessment Aid submitted to FDA (Study 04 – Schematic of Study Design)24